MicroRNAs, promising biomarkers in the diagnosis of Xp11 translocation RCC

Renal cell carcinomas (RCCs) with Xp11 translocation/TFE3 gene fusions (Xp11 RCC) are a characteristic subtype of RCC, distinguished by chromosomal translocations with breakpoints of the TFE3 transcription factor gene, which point to the Xp11.2 locus [1]. Xp11 translocation RCCs are the majority of pediatric RCC with a high degree of malignancy, but only 1%–4% of adult RCC [2]. At present, no standard treatment protocol for a sick person with Xp11 translocation RCC has been found. Research shows that clinical symptoms, image characteristics and pathologic characteristics of Xp11 translocation RCC are similar to other RCC subtypes [3,4].

http://ift.tt/2hUO44L